<p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）预计将在 2026 年 5 月 5 日星期二市场开盘前发布其 2026 年第一季度的财报。分析师预计 LifeMD 将发布每股收益（$0.14）和本季度营收为 4869.20 万美元。感兴趣的人员被鼓励访问公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 6 日下午 4:30（东部时间）的电话会议的最新详情。</p>
<ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
<p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）最近在 3 月 9 日星期一发布了其财报。公司报告本季度每股收益为（$0.04），低于分析师一致预期的（$0.01），差距为（$0.03）。LifeMD 的净利润率为 6.58%，股本回报率为负的 83.93%。公司本季度的营收为 4687 万美元，而分析师的预期为 4857 万美元。平均而言，分析师预计 LifeMD 在当前财年将发布每股收益为$0，在下一个财年也将发布每股收益为$0。</p>
<h2>LifeMD 价格表现</h2>
<p>在周二的午盘交易中，LFMD 股票下跌了$0.08，达到$4.50。该公司的交易量为 235,635 股，而其平均交易量为 1,179,324 股。该公司的 50 日移动平均价格为$3.64，200 日移动平均价格为$4.00。LifeMD 的 1 年最低价为$2.56，1 年最高价为$15.84。该公司的市值为 2.1563 亿美元，市盈率为 17.21，贝塔值为 1.77。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
<p>多家股票研究分析师对该股票发表了评论。Loop Capital 在 3 月 12 日星期四的研究报告中将 LifeMD 的目标价设定为$10.00。Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 LifeMD 的 “卖出（e+）” 评级。Mizuho 在 3 月 16 日星期一将 LifeMD 的评级从 “中性” 上调至 “跑赢大盘”，并将该股票的目标价从$6.00 提高至$8.00。BTIG Research 在 3 月 10 日星期二的报告中重申了 “买入” 评级，并将 LifeMD 的目标价设定为$10.00。最后，HC Wainwright 在 3 月 11 日星期三的研究报告中将 LifeMD 的目标价从$9.00 提高至$10.00，并给予公司 “买入” 评级。七位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为$9.14。</p>
<p><strong>阅读我们对 LifeMD 的最新股票分析</strong></p>
<h2>LifeMD 的机构交易</h2>
<ul>
<li>LifeMD 可以凭借其 GLP-1 产品大幅上涨</li>
</ul>
<p>对冲基金最近调整了对该公司的持股。Virtu Financial LLC 在第四季度新购入了 LifeMD 的股份，价值$155,000。Invesco Ltd.在第四季度将其在 LifeMD 的股份增加了 18.8%。Invesco Ltd.现在拥有 24,464 股该公司的股票，价值$83,000，此前在上个季度又购买了 3,870 股。XTX Topco Ltd 在第四季度将其在 LifeMD 的持股增加了 9.0%。XTX Topco Ltd 现在拥有 82,360 股该公司的股票，价值$281,000，此前在上个季度又收购了 6,814 股。Millennium Management LLC 在第四季度将其在 LifeMD 的持股增加了 220.8%。Millennium Management LLC 现在拥有 216,836 股该公司的股票，价值$739,000，此前在上个季度又收购了 149,234 股。最后，Bridgeway Capital Management LLC 在第四季度将其在 LifeMD 的持股增加了 74.4%。Bridgeway Capital Management LLC 现在拥有 76,200 股该公司的股票，价值$260,000，此前在上个季度又收购了 32,500 股。对冲基金和其他机构投资者持有该公司 35.52% 的股份。</p>
<h2>关于 LifeMD</h2>
<p>（获取免费报告）</p>
<p>LifeMD（纳斯达克：LFMD）是一家总部位于美国的远程医疗公司，提供按需的会员制虚拟医疗服务。通过其数字平台和移动应用程序，LifeMD 将患者与经过认证的医疗提供者连接，以进行各种急性和慢性病症的诊断、治疗和持续管理。公司的核心服务围绕个性化护理计划，支持处方履行、实验室检测和处方配送服务。</p>
<p>LifeMD 的服务组合涵盖多个专业领域，包括男性健康、激素治疗、体重管理和初级护理。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 LifeMD</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 LifeMD 吗？</h2>
<p>在你考虑投资 LifeMD 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 LifeMD 并不在名单上。</p>
<p>虽然 LifeMD 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LFMD

美国医疗保健供应商 ETF - iShares

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

标普医疗保健服务 ETF - SPDR

<p>LifeMD（纳斯达克代码：LFMD）定于 5 月 5 日发布 2026 年第一季度财报，分析师预测每股亏损 0.14 美元，收入为 4869 万美元。该公司此前报告了 2025 年第一季度每股亏损 0.04 美元，未能达到预期。LifeMD 的股票目前交易价格为 4.50 美元，市值为 2.1563 亿美元。分析师对该公司的评级褒贬不一，普遍目标价为 9.14 美元。对冲基金已增加在该公司的持股，该公司专注于远程医疗服务</p>

<p>LifeMD (NASDAQ:LFMD - Get Free Report) is projected to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect LifeMD to post earnings of ($0.14) per share and revenue of $48.6920 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）预计将在 2026 年 5 月 5 日星期二市场开盘前发布其 2026 年第一季度的财报。分析师预计 LifeMD 将发布每股收益（$0.14）和本季度营收为 4869.20 万美元。感兴趣的人员被鼓励访问公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 6 日下午 4:30（东部时间）的电话会议的最新详情。</p>
</div><ul>
<li>Can the New CEO Revive This Struggling Telehealth Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>新任首席执行官能否振兴这只挣扎中的远程医疗股票？</li>
</ul>
</div><p>LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.03). LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. The company had revenue of $46.87 million for the quarter, compared to analysts' expectations of $48.57 million. On average, analysts expect LifeMD to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克代码：LFMD - 获取免费报告）最近在 3 月 9 日星期一发布了其财报。公司报告本季度每股收益为（$0.04），低于分析师一致预期的（$0.01），差距为（$0.03）。LifeMD 的净利润率为 6.58%，股本回报率为负的 83.93%。公司本季度的营收为 4687 万美元，而分析师的预期为 4857 万美元。平均而言，分析师预计 LifeMD 在当前财年将发布每股收益为$0，在下一个财年也将发布每股收益为$0。</p>
</div><h2>LifeMD Price Performance</h2>
<div class="lb-trans"><h2>LifeMD 价格表现</h2>
</div><p>LFMD stock traded down $0.08 during midday trading on Tuesday, reaching $4.50. The company had a trading volume of 235,635 shares, compared to its average volume of 1,179,324. The firm has a 50-day moving average price of $3.64 and a 200-day moving average price of $4.00. LifeMD has a 1 year low of $2.56 and a 1 year high of $15.84. The company has a market capitalization of $215.63 million, a P/E ratio of 17.21 and a beta of 1.77.</p>
<div class="lb-trans"><p>在周二的午盘交易中，LFMD 股票下跌了$0.08，达到$4.50。该公司的交易量为 235,635 股，而其平均交易量为 1,179,324 股。该公司的 50 日移动平均价格为$3.64，200 日移动平均价格为$4.00。LifeMD 的 1 年最低价为$2.56，1 年最高价为$15.84。该公司的市值为 2.1563 亿美元，市盈率为 17.21，贝塔值为 1.77。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 计划而飙升</li>
</ul>
</div><p>A number of equities research analysts have commented on the stock. Loop Capital set a $10.00 target price on shares of LifeMD in a research report on Thursday, March 12th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of LifeMD in a research report on Friday, March 27th. Mizuho upgraded LifeMD from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their target price for the stock from $6.00 to $8.00 in a research report on Monday, March 16th. BTIG Research reaffirmed a &#34;buy&#34; rating and set a $10.00 price objective on shares of LifeMD in a report on Tuesday, March 10th. Finally, HC Wainwright increased their price objective on shares of LifeMD from $9.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, March 11th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.14.</p>
<div class="lb-trans"><p>多家股票研究分析师对该股票发表了评论。Loop Capital 在 3 月 12 日星期四的研究报告中将 LifeMD 的目标价设定为$10.00。Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 LifeMD 的 “卖出（e+）” 评级。Mizuho 在 3 月 16 日星期一将 LifeMD 的评级从 “中性” 上调至 “跑赢大盘”，并将该股票的目标价从$6.00 提高至$8.00。BTIG Research 在 3 月 10 日星期二的报告中重申了 “买入” 评级，并将 LifeMD 的目标价设定为$10.00。最后，HC Wainwright 在 3 月 11 日星期三的研究报告中将 LifeMD 的目标价从$9.00 提高至$10.00，并给予公司 “买入” 评级。七位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为$9.14。</p>
</div><p><strong>Read Our Latest Stock Analysis on LifeMD</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 LifeMD 的最新股票分析</strong></p>
</div><h2>Institutional Trading of LifeMD</h2>
<div class="lb-trans"><h2>LifeMD 的机构交易</h2>
</div><ul>
<li>LifeMD Can Surge on Its GLP-1 Offerings</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 可以凭借其 GLP-1 产品大幅上涨</li>
</ul>
</div><p>Hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of LifeMD in the fourth quarter worth $155,000. Invesco Ltd. grew its stake in shares of LifeMD by 18.8% in the 4th quarter. Invesco Ltd. now owns 24,464 shares of the company's stock valued at $83,000 after buying an additional 3,870 shares in the last quarter. XTX Topco Ltd raised its position in LifeMD by 9.0% during the fourth quarter. XTX Topco Ltd now owns 82,360 shares of the company's stock valued at $281,000 after acquiring an additional 6,814 shares in the last quarter. Millennium Management LLC lifted its stake in LifeMD by 220.8% in the fourth quarter. Millennium Management LLC now owns 216,836 shares of the company's stock valued at $739,000 after acquiring an additional 149,234 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its position in LifeMD by 74.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 76,200 shares of the company's stock worth $260,000 after acquiring an additional 32,500 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近调整了对该公司的持股。Virtu Financial LLC 在第四季度新购入了 LifeMD 的股份，价值$155,000。Invesco Ltd.在第四季度将其在 LifeMD 的股份增加了 18.8%。Invesco Ltd.现在拥有 24,464 股该公司的股票，价值$83,000，此前在上个季度又购买了 3,870 股。XTX Topco Ltd 在第四季度将其在 LifeMD 的持股增加了 9.0%。XTX Topco Ltd 现在拥有 82,360 股该公司的股票，价值$281,000，此前在上个季度又收购了 6,814 股。Millennium Management LLC 在第四季度将其在 LifeMD 的持股增加了 220.8%。Millennium Management LLC 现在拥有 216,836 股该公司的股票，价值$739,000，此前在上个季度又收购了 149,234 股。最后，Bridgeway Capital Management LLC 在第四季度将其在 LifeMD 的持股增加了 74.4%。Bridgeway Capital Management LLC 现在拥有 76,200 股该公司的股票，价值$260,000，此前在上个季度又收购了 32,500 股。对冲基金和其他机构投资者持有该公司 35.52% 的股份。</p>
</div><h2>About LifeMD</h2>
<div class="lb-trans"><h2>关于 LifeMD</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company's core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.</p>
<div class="lb-trans"><p>LifeMD（纳斯达克：LFMD）是一家总部位于美国的远程医疗公司，提供按需的会员制虚拟医疗服务。通过其数字平台和移动应用程序，LifeMD 将患者与经过认证的医疗提供者连接，以进行各种急性和慢性病症的诊断、治疗和持续管理。公司的核心服务围绕个性化护理计划，支持处方履行、实验室检测和处方配送服务。</p>
</div><p>LifeMD's service portfolio spans several specialty areas, including men's health, hormonal therapy, weight management and primary care.</p>
<div class="lb-trans"><p>LifeMD 的服务组合涵盖多个专业领域，包括男性健康、激素治疗、体重管理和初级护理。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than LifeMD</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 LifeMD</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LifeMD Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 LifeMD 吗？</h2>
</div><p>Before you consider LifeMD, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 LifeMD 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 LifeMD 并不在名单上。</p>
</div><p>While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LifeMD 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LifeMD (LFMD) 预计将在周二发布季度财报